Considering the results of the 3D model and the cell migration studies together, it appears that a combined therapy with RUX/DOXY/TGF-β1 is a potential treatment for skin ulcerations in ISG15 deficiency, but that the effects of TGF-β1 on cell migration require clarification. This evidence concerns the gene TGFB1 and Skin ulcer.